Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers.
Eight healthy volunteers were given single subcutaneous doses of dermatan sulfate (DS, 100, 200 and 400 mg), heparin (5,000 IU) and placebo in random order. Wash-out between treatments was greater than or equal to 10 days. Serial blood samples were taken before and up to 24 hours after treatment to measure coagulation and fibrinolytic parameters. Thrombin generation was significantly inhibited by DS and heparin as compared to placebo. The effect of DS was dose-dependent. Peak inhibition after 200 mg DS was comparable to that of 5,000 IU heparin, but lasted longer. A small, bordeline significant prolongation of APTT was observed after 400 mg DS and heparin. The changes in PAI and fibrinolytic activities were those of the circadian variation. No changes were seen in the other parameters tested. In conclusion, single s.c. doses of DS (200, or 400 mg) inhibit ex vivo thrombin generation equally or more than 5,000 IU heparin and for a longer time. The effect of both treatments on fibrinolysis is negligible.
A. Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Italy.
A
A
Tripodi
M
M
Moia
B
B
Bottasso
P M
PM
Tenconi
F
F
Gianese
P M
PM
Mannucci
D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D002940:Circadian Rhythm; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D010314:Partial Thromboplastin Time; D015849:Plasminogen Inactivators / Q000032:analysis; D013917:Thrombin / Q000096:biosynthesis
D000925:Anticoagulants; D015849:Plasminogen Inactivators; D003871:Dermatan Sulfate; D006493:Heparin; D013917:Thrombin